ScreenerHero

SRRK Scholar Rock Holding Corporation

NAS · US · Healthcare · Biotechnology · scholarrock.com
42.20USD-0.59%Mkt Cap: 5.14B $P/E: —

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.14B USD
Enterprise Value4.88B USD
Revenue (TTM)—
Gross Profit-207.41M USD
Net Income (TTM)-377.94M USD
Revenue/Share—
Last Price42.20 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees289
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-16.66
PEG—
EV/EBITDA-12.06
EV/Revenue—
P/S—
P/B20.34
EPS (TTM)-3.32
EPS (Forward)-2.55
52W Range
27.0744% of range61.75
52W High61.75 USD
52W Low27.07 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-153.95%
ROA-93.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-300.04M USD
CapEx (TTM)602.00K USD
FCF Margin—
FCF Yield-2.99%
Net Debt-288.26M USD
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity0.44
Current Ratio7.02
Quick Ratio6.84
Book Value/Sh2.09 USD
Cash/Share4.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)70.44 USD
Upside (mean)+66.9%
Target Range58.00 USD – 84.00 USD
58.00+66.9% to mean84.00
# Analysts16
Ownership
Shares Out.121.79M
Float104.09M
Insiders0.73%
Institutions117.57%
Short Interest
Short Ratio13.0d
Short % Float19.89%
Short % Out.15.94%
Shares Short19.41M
Short (prev mo.)18.22M
Technical
SMA 5052.01 (-18.9%)
SMA 20048.40 (-12.8%)
Beta0.62
S&P 52W Chg16.45%
Avg Vol (30d)1.68M
Avg Vol (10d)1.97M
Technical Indicators
RSI (14)31.4
MACD-2.5827
MACD Signal-1.6959
MACD Hist.-0.8868
BB Upper58.49 USD
BB Middle49.57 USD
BB Lower40.66 USD
BB Width35.96%
ATR (14)2.642 USD
Vol Ratio (20d)0.80x